Medo.ai receives FDA approval for first AI-based thyroid ultrasound
By
Hiba Kamal-Choufi
in the
Health Innovation Roundup
The U.S. Food and Drug Administration (FDA) has approved Medo.ai's AI-based thyroid ultrasound system.
Medo-Thyroid uses artificial intelligence to simplify thyroid ultrasounds through a faster and more accurate diagnosis — the company said it's the world's first tool to do this.
It uses algorithms to automatically analyze scans of the thyroid gland, then locates, measures, and characterizes nodules or lumps using the existing Thyroid Imaging Reporting and Data System (TI-RADS).
"We applied artificial intelligence to make the process fast, so (caregivers) no longer have to fish around. They can just take a sweep instead, and then our AI automatically takes over and identifies the measurements with no assistance at all. It will then come up with TI-RADS classifications, which are used to determine whether (nodules) are cancerous or problematic enough that they require a biopsy," Medo.ai co-founder David Quail told Taproot.